PAVmed Inc. (PAVM): Price and Financial Metrics


PAVmed Inc. (PAVM): $0.66

0.01 (+1.84%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

PAVM POWR Grades

  • Sentiment is the dimension where PAVM ranks best; there it ranks ahead of 28.8% of US stocks.
  • The strongest trend for PAVM is in Momentum, which has been heading down over the past 179 days.
  • PAVM's current lowest rank is in the Quality metric (where it is better than 0.59% of US stocks).

PAVM Stock Summary

  • PAVM's price/sales ratio is 115.43; that's higher than the P/S ratio of 97.93% of US stocks.
  • With a year-over-year growth in debt of 1,192.35%, PAVMED INC's debt growth rate surpasses 98.19% of about US stocks.
  • As for revenue growth, note that PAVM's revenue has grown 182.5% over the past 12 months; that beats the revenue growth of 95.55% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to PAVMED INC, a group of peers worth examining would be IGC, AFRM, PD, SLGC, and S.
  • Visit PAVM's SEC page to see the company's official filings. To visit the company's web site, go to www.pavmed.com.

PAVM Valuation Summary

  • PAVM's EV/EBIT ratio is -0.6; this is 106.98% lower than that of the median Healthcare stock.
  • PAVM's EV/EBIT ratio has moved up 96.6 over the prior 77 months.

Below are key valuation metrics over time for PAVM.

Stock Date P/S P/B P/E EV/EBIT
PAVM 2022-11-25 124.4 7.9 -0.8 -0.6
PAVM 2022-11-23 126.0 8.0 -0.8 -0.6
PAVM 2022-11-22 123.0 7.8 -0.8 -0.6
PAVM 2022-11-21 128.1 8.1 -0.8 -0.6
PAVM 2022-11-18 132.7 8.4 -0.9 -0.7
PAVM 2022-11-17 139.6 8.8 -0.9 -0.7

PAVM Growth Metrics

    Its 5 year net cashflow from operations growth rate is now at -198.07%.
  • Its 2 year cash and equivalents growth rate is now at 641.46%.
  • The 5 year price growth rate now stands at -68.57%.
Over the past 33 months, PAVM's revenue has gone up $565,000.

The table below shows PAVM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 0.565 -70.939 -86.017
2022-06-30 0.689 -59.616 -72.114
2022-03-31 0.689 -43.686 -58.064
2021-12-31 0.5 -40.591 -50.63
2021-09-30 0.2 -30.542 -42.157
2021-06-30 0 -28.364 -35.42

PAVM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PAVM has a Quality Grade of D, ranking ahead of 12.56% of graded US stocks.
  • PAVM's asset turnover comes in at 0 -- ranking 171st of 186 Medical Equipment stocks.
  • BBLG, SNN, and EYE are the stocks whose asset turnover ratios are most correlated with PAVM.

The table below shows PAVM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 NA 21.356
2021-03-31 0 NA 13.527
2020-12-31 0 NA 10.749
2020-09-30 0 NA 9.995
2020-06-30 0 NA 9.541
2020-03-31 0 NA 9.891

PAVM Price Target

For more insight on analysts targets of PAVM, see our PAVM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.08 Average Broker Recommendation 1.5 (Moderate Buy)

PAVM Stock Price Chart Interactive Chart >

Price chart for PAVM

PAVM Price/Volume Stats

Current price $0.66 52-week high $3.85
Prev. close $0.65 52-week low $0.58
Day low $0.58 Volume 1,180,898
Day high $0.67 Avg. volume 1,297,142
50-day MA $0.97 Dividend yield N/A
200-day MA $1.18 Market Cap 60.07M

PAVmed Inc. (PAVM) Company Bio


PAVmed Inc. operates as a medical device company in the United States. Its product pipeline includes PortIO, a long-term implantable vascular access device; CarpX, a percutaneous device to treat carpal tunnel syndrome; NextCath, a self-anchoring catheter; DisappEAR: Antibiotic-eluting resorbable ear tube; NextFlo, a disposable infusion pump; and Caldus, a disposable tissue ablation device. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was founded in 2014 and is based in New York, New York.


PAVM Latest News Stream


Event/Time News Detail
Loading, please wait...

PAVM Latest Social Stream


Loading social stream, please wait...

View Full PAVM Social Stream

Latest PAVM News From Around the Web

Below are the latest news stories about PAVMED INC that investors may wish to consider to help them evaluate PAVM as an investment opportunity.

Analysts Offer Insights on Healthcare Companies: Theravance Biopharma (TBPH), Cogent Biosciences (COGT) and PAVmed (PAVM)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Theravance Biopharma (TBPH – Research Report), Cogent Biosciences (COGT – Research Report) and PAVmed (PAVM – Research Report) with bullish sentiments. Theravance Biopharma (TBPH) SVB Securities analyst David Risinger maintained a Buy rating on Theravance Biopharma today and set a price target of $14.00. The company's shares closed last Wednesday at $11.22. According to TipRanks.

Brian Anderson on TipRanks | November 17, 2022

PAVmed Provides Business Update and Third Quarter 2022 Financial Results

NEW YORK, November 15, 2022--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and presented financial results for the three and nine months ended September 30, 2022.

Yahoo | November 15, 2022

Lucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results

NEW YORK, November 14, 2022--Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today provided a business update for the Company and presented financial results for the three and nine months ended September 30, 2022.

Yahoo | November 14, 2022

PAVmed to Participate in BTIG Digital Health Forum

NEW YORK, November 11, 2022--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed", the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today announced that Lishan Aklog, M.D., PAVmed’s Chairman and CEO, will participate in the Technologies Ushering in Next-Generation Diagnostics, Therapies, and Surgeries virtual panel discussion on November 21, 2022 from 12:00 pm to 12:55 pm EST at the BTIG Digital Health Foru

Yahoo | November 11, 2022

Lucid Diagnostics to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum

NEW YORK, November 10, 2022--Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid", the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced that Lishan Aklog, M.D., the Lucid’s Chairman and Chief Executive Officer, will present an overview of the Company at the CG MedTech, Diagnostics and Digital Health & Services Forum taking place on November 17, 2022 from 11:00 am to 11:25 am EST

Yahoo | November 10, 2022

Read More 'PAVM' Stories Here

PAVM Price Returns

1-mo -46.77%
3-mo -43.59%
6-mo -34.65%
1-year -82.02%
3-year -24.05%
5-year -77.70%
YTD -73.17%
2021 16.04%
2020 76.67%
2019 24.74%
2018 -57.90%
2017 -66.88%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7228 seconds.